Article

Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 COVE Trial

2021-12-29

Abstract excerpt

Background: The mRNA-1273 vaccine demonstrated an acceptable safety profile and 93·2% efficacy at preventing Coronavirus disease 2019 (COVID-19) in the Coronavirus efficacy (COVE) trial. We report the immunogenicity results of the trial.<br><br>Methods: mRNA-1273 vaccine or placebo were given 28 days apart in a 1:1 ratio. Serologic immune responses were evaluated in a pre-specified per-protocol immunogenicity popu...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 85d9eccf-57f9-5b2e-ac16-7a49806368d9
DOI: 10.2139/ssrn.3988003

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 COVE TrialDOI 10.2139/ssrn.3988003Read

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine — An Interim AnalysisSemantic proximity Read

Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain and N-Terminal Domain mRNA VaccineSemantic proximity Read

Reactogenicity, Safety, and Serological and Cellular Immunogenicity of a Booster Dose of SARS-CoV-2 mRNA Prototype, Variant, and Bivalent VaccinesSemantic proximity Read

Interim Analysis of a Phase I Randomized Clinical Trial on the Safety and Immunogenicity of the mRNA-1283 SARS-CoV-2 Vaccine in AdultsSemantic proximity Read

Initial Analysis of Viral Dynamics and Circulating Viral Variants During the mRNA-1273 Phase 3 COVE TrialSemantic proximity Read

Preliminary Analysis of Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine BoosterSemantic proximity Read

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older AdultsSemantic proximity Read

Immunogenicity and Reactogenicity of Heterologous and Homologous mRNA-1273 and BNT162b2 Vaccination: A Multicenter Non-Inferiority Randomized TrialSemantic proximity Read

Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trialSemantic proximity Read

Elasomeran (mRNA1273) Vaccine: The Journey from Preclinical Research to Clinical Trials, Authorization, and FDA ApprovalSemantic proximity Read

Real-World Effectiveness of the mRNA-1273 Vaccine Against COVID-19: Interim Results from a Prospective Observational Cohort StudySemantic proximity Read

Safety and Immunogenicity of a 100 μg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)Semantic proximity Read